Legend Biotech (LEGN) Reports CARVYKTI Approved in EU streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Scotiabank upgraded shares of Legend Biotech (NASDAQ:LEGN – Free Report) from a sector perform rating to a sector outperform rating in a research note published on Wednesday, MarketBeat reports. The firm currently has $65.00 price target on the stock. A number of other research firms have also issued reports on LEGN. Raymond James assumed coverage […]
Scotiabank Upgrades Legend Biotech (NASDAQ:LEGN) to Sector Outperform themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
HC Wainwright restated their buy rating on shares of Legend Biotech (NASDAQ:LEGN – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $87.00 price objective on the stock. HC Wainwright also issued estimates for Legend Biotech’s Q1 2024 earnings at ($0.01) EPS and Q3 2024 earnings […]